南方科技大学知识苑(SUSTech KC): Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial

题名	Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
作者	Zou, Rongrong 1; Peng, Ling 1; Shu, Dan 1; Zhao, Lei 2; Lan, Jianfeng 1; Tan, Guoyu 1; Peng, Jinghan 1; Yang, Xiangyi 1; Liu, Miaona 1; Zhang, Chenhui1 ; Yuan, Jing1 ; Wang, Huxiang 1; Li, Song 2; Lu, Hongzhou 1; Zhong, Wu 2; Liu, Yingxia 1
通讯作者	Li, Song; Lu, Hongzhou; Zhong, Wu; Liu, Yingxia
发表日期	2022-06-15
DOI	10.3389/fphar.2022.939573
发表期刊	FRONTIERS IN PHARMACOLOGY 影响因子和分区
EISSN	1663-9812
卷号	13
摘要	Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved drug, is still unknown in patients infected with the Omicron variant.Objective: Evaluated the antiviral efficacy and safety of molnupiravir in patients infected with SARS-CoV-2 Omicron variant, with symptom duration within 5 days. Methods: We conducted a randomized, controlled trial involving patients with mild or moderate COVID-19. Patients were randomized to orally receive molnupiravir (800 mg) plus basic treatment or only basic treatment for 5 days (BID). The antiviral efficacy of the drug was evaluated using reverse transcriptase polymerase chain reaction. Results: Results showed that the time of viral RNA clearance (primary endpoint) was significantly decreased in the molnupiravir group (median, 9 days) compared to the control group (median, 10 days) (Log-Rank p = 0.0092). Of patients receiving molnupiravir, 18.42% achieved viral RNA clearance on day 5 of treatment, compared to the control group (0%) (p = 0.0092). On day 7, 40.79%, and 6.45% of patients in the molnupiravir and control groups, respectively, achieved viral RNA clearance (p = 0.0004). In addition, molnupiravir has a good safety profile, and no serious adverse events were reported. Conclusion: Molnupiravir significantly accelerated the SARS-CoV-2 Omicron RNA clearance in patients with COVID-19.
关键词	Omicron variant SARS-CoV-2 molnupiravir antiviral efficacy clinical trial
相关链接	[来源记录]
收录类别	SCI
语种	英语
学校署名	第一 ; 通讯
资助项目	National Key Research and Development Project[2021YFC2300704] ; Shenzhen Science and Technology Research and Development Project[JSGG20200207161928126] ; National Science and Technology[2018ZX09711003]
WOS研究方向	Pharmacology & Pharmacy
WOS类目	Pharmacology & Pharmacy
WOS记录号	WOS:000820058300001
出版者	FRONTIERS MEDIA SA
来源库	Web of Science
引用统计	被引频次[WOS]：35
成果类型	期刊论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/353412
专题	南方科技大学第二附属医院南方科技大学第一附属医院
作者单位	1.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis, Shenzhen Key Lab Pathogen & Immun,Hosp Affiliated, Shenzhen, Peoples R China 2.Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing, Peoples R China
第一作者单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
通讯作者单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
第一作者的第一单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
推荐引用方式 GB/T 7714	Zou, Rongrong,Peng, Ling,Shu, Dan,et al. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial[J]. FRONTIERS IN PHARMACOLOGY,2022,13.
APA	Zou, Rongrong.,Peng, Ling.,Shu, Dan.,Zhao, Lei.,Lan, Jianfeng.,...&Liu, Yingxia.(2022).Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.FRONTIERS IN PHARMACOLOGY,13.
MLA	Zou, Rongrong,et al."Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial".FRONTIERS IN PHARMACOLOGY 13(2022).